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Abstract
Background: A shift towards less burdening and more patient friendly treatments for breast cancer is currently
ongoing. In low-risk patients with early-stage disease, accelerated partial breast irradiation (APBI) is an alternative for
whole breast irradiation following breast-conserving surgery. MRI-guided single dose ablative APBI has the potential
to offer a minimally burdening, non-invasive treatment that could replace current breast-conserving therapy.
Methods: The ABLATIVE study is a prospective, single arm, multicenter study evaluating preoperative, single dose,
ablative radiation treatment in patients with early-stage breast cancer. Patients with core biopsy proven non-lobular
invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI)
and a negative sentinel node biopsy are eligible. Radiotherapy (RT) planning will be performed using a contrast
enhanced (CE) planning CT-scan, co-registered with a CE-MRI, both in supine RT position. A total of twenty-five
consecutive patients will be treated with a single ablative RT dose of 20 Gy to the tumor and 15 Gy to the
tumorbed. Follow-up MRIs are scheduled within 1 week, 2, 4 and 6 months after single-dose RT. Breast-conserving
surgery is scheduled at six months following RT.
Primary study endpoint is pathological complete response. Secondary study endpoints are the radiological response
and toxicity. Furthermore, patients will fill out questionnaires on quality of life and functional status. Cosmetic
outcome will be evaluated by the treating radiation oncologist, patient and ‘Breast Cancer Conservation Treatment
cosmetic results’ software. Recurrence and survival rates will be assessed. The patients will be followed up to
10 years after diagnosis. If patients give additional informed consent, a biopsy and a part of the irradiated specimen
will be stored at the local Biobank and used for future research on radiotherapy response associated genotyping.
Discussion: The ABLATIVE study evaluates MRI-guided single dose ablative RT in patients with early-stage breast
cancer, aiming at a less burdening and non-invasive alternative for current breast-conserving treatment.
Trial registration: ClinicalTrials.gov registration number NCT02316561. The trial was registrated prospectively on
October 10th 2014.
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Background
In the field of breast cancer treatment a shift towards
less burdening and more patient friendly therapies is
currently ongoing. Breast-conserving therapy consisting
of breast-conserving surgery (BSC) followed by whole
breast irradiation (WBI) is the standard treatment for
early-stage disease [1, 2]. The WBI benefit with respect
to local recurrence and breast cancer associated mortal-
ity varies substantially, depending on clinical and tumor
characteristics [3, 4].
A main shortcoming of WBI is the protracted schedule
of 16 to 23 RT fractions, ranging from 3 to 5 weeks
treatment duration. Since the risk of local recurrence is
low, and 62 to 88% of local recurrences are found within
the vicinity of the tumor bed [5, 6], accelerated partial
breast irradiation (APBI) has been investigated as an al-
ternative to WBI. APBI can deliver a higher radiation
dose solely on breast tissue directly surrounding the
tumor bed in a reduced treatment time [7–9]. APBI in-
stead of WBI following breast-conserving surgery can
represent a less burdening treatment, however adequate
patient selection is essential. APBI, when compared to
WBI, can be associated with an increased local recur-
rence rate in high-risk patients, without compromising
regional and distance recurrence or overall survival [10–
18]. In selected patients with early-stage and low-risk
characteristics, APBI can be regarded as an equivalent to
WBI [18, 19]. Patient eligibility guidelines for APBI have
been set up by the American Society for Radiation On-
cology (ASTRO) and European Society for Radiotherapy
and Oncology (ESTRO) [7, 8].
Adequate delivery of APBI is critical given that RT is
aimed for high-risk tissue only and not the whole breast.
Target volume definition is more precise before surgical
tumor removal, when compared to a post-operative ap-
proach [20]. In addition, there is with less variability in
target volume delineation across radiation oncologists
[20, 21]. Also, a substantial reduction in treatment vol-
umes can be achieved with preoperative APBI when
compared with post-operative APBI, possibly leading to
less treatment-related toxicity [20, 22, 23].
MRI-guided single dose APBI, prior to breast-conserving
surgery, has been investigated in women with early-stage
and low-risk breast cancer due to its potential to minimize
RT treatment duration and toxicity [24]. However, a pri-
mary ablative RT approach to the tumor, without the per-
formance of breast-conserving surgery, may represent an
additional gain for the clinical practice. As with stereotactic
RT for stage I non-small-cell lung cancer [25], non-
invasive, ablative RT might be feasible as definitive treat-
ment for early-stage breast cancer. Single dose ablative
APBI has the potential to decrease the burden of multiple
RT fractions, and at the same time replace breast-
conserving surgery for selected patients. This could offer a
non-invasive and minimally burdening treatment for
women with early-stage breast cancer.
A multicenter, single-arm prospective study has been
initiated in The Netherlands, in order to evaluate MRI-
guided single dose ablative RT as definitive treatment for
early-stage breast cancer. This paper describes the study
design, which assesses an ablative treatment approach
following single dose MRI-guided APBI in breast cancer.
Methods/design
Study design
The ABLATIVE trial was initiated as a single-arm pro-
spective interventional study at the Radiotherapy De-
partment of the University Medical Center (UMC)
Utrecht in The Netherlands and was subsequently ex-
tended to 3 regional peripheral hospitals. The purpose of
the study is to evaluate the feasibility of single dose
radiotherapy as definitive treatment for early-stage
breast cancer. To evaluate the pathological tumor re-
sponse, breast-conserving surgery is performed at
6 months after RT. The primary study endpoint is the
pathological complete response (pCR) as assessed by
microscopic evaluation of the excision specimen. The
secondary endpoints include radiological response, tox-
icity, cosmetic outcome, local, regional and distant re-
lapse rates, and disease-free and overall survival. Also,
patient reported outcome measures such as quality of
life, functionality, psychological symptoms and frailty are
evaluated. Furthermore, if patients provide additional in-
formed consent for Biobank purposes, future research
will evaluate radiotherapy response genotyping.
Ethical matters
This study is set-up in agreement with the Declaration
of Helsinki (Fortaleza, Brazil, October 2013) and is con-
ducted in accordance with the Dutch Medical Research
Involving Human Subjects Act (http://www.ccmo.nl).
The study protocol has been approved by the Medical
Research Ethics Committee of the UMC Utrecht
(NL46017.041.13) and has been recorded in an inter-
national trial registry (ClinicalTrial.gov: NCT02316561).
The study has been approved by the Institutional Review
Board of each participating institute. Written informed
consent is obtained from all patients before inclusion.
Quality assurance
Study monitoring will be carried out centrally at the
UMC Utrecht, by an independent monitor contracted by
the sponsor, according to national guidelines on quality
control for university medical centers [26].
Patient recruitment and selection
Women presenting at the Department of Surgery of the
UMC Utrecht and Diakonessenhuis hospital in Utrecht,
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St. Antonius Hospital in Nieuwegein/Utrecht or Rivier-
enland Hospital in Tiel are eligible for inclusion after a
diagnosis of invasive breast cancer. The study initially in-
cluded patients at least 60 years of age with early-stage
and low-risk (cT1N0Mx) invasive ductal or ductulobular
breast cancer without an indication for systemic treat-
ment according to Dutch National Guidelines. Recently,
eligibility criteria were broadened to include patients
from 50 years or older, and the use of endocrine treat-
ment was permitted. Table 1 gives an overview on the
inclusion and exclusion criteria, which are in concord-
ance to the ASTRO and ESTRO guidelines for partial
breast irradiation [7, 8].
The surgeon informs patients on the possibility of a
study intervention evaluating single dose RT with post-
poned surgical treatment instead of standard of care 16–
23 fractions postoperative radiotherapy. Patients inter-
ested in trial participation receive additional information
from the coordinating investigator. Furthermore, these
patients are referred to the radiation oncologist at the
UMC Utrecht for preoperative consultation to receive
information about the standard RT treatment.
Procedures
An overview of the required study procedures for single
dose ablative radiotherapy is illustrated in Fig. 1. All patients
will undergo the RT study procedures at the UMC Utrecht.
Study patients from the participating teaching hospitals will
undergo the standard of care sentinel node procedure and
breast-conserving surgery in the referral hospital.
Diagnostic work-up
Following informed consent, eligibility criteria are assessed
stepwise. First, the estrogen, progesterone and HER2 re-
ceptor, and Bloom & Richardson tumor grade are assessed
on a 14-gauge histological biopsy [27]. Second, a diagnos-
tic MRI (in prone position) is performed to assess the
tumor diameter and exclude tumor multifocality or multi-
centricity [28]. A third step is the performance of a senti-
nel node procedure, using blue dye, separately from
breast-conserving surgery. Only patients with a pN0 nodal
status are eligible [7, 8]. For the purpose of RT response
assessment, an FDG-PET-CT of the breasts is performed
to acquire a baseline standard uptake value (SUV) of the
tumor before irradiation.
Radiotherapy preparations
For position verification purposes during RT delivery, an
MRI compatible clip will be placed in the tumor under
ultrasound guidance. For RT treatment planning, a
contrast-enhanced (CE) CT-scan as well as CE and func-
tional MRI-scan in supine RT treatment position are per-
formed on the same day. The gross tumor volume (GTV)
is delineated on CE-CT, and co-registered with the find-
ings on CE-MRI by a radiation oncologist specialized in
breast cancer. GTV delineation is verified by a dedicated
breast radiologist. To account for microscopic disease, the
GTV is uniformly expanded by 2 cm to create a clinical
target volume (CTV), thereby excluding the first 5 mm
beneath the skin and the chest wall. Both GTV and CTV
are uniformly expanded by 3 mm to obtain the planning
target volumes PTVGTV and PTVCTV, respectively, thereby
excluding the first 5 mm beneath the skin [29, 30]. Organs
at risk (OARs), such as skin, ipsilateral and contralateral
breast, lungs, heart and chest wall are delineated accord-
ing to predefined protocols [29]. Figure 2 illustrates the
delineations of the target volumes and OARs.
Volumetric modulated arc therapy (VMAT) plans are
created using 2 separated partial arcs, clockwise and
counter clockwise. Two radiotherapy dose levels are
concomitantly prescribed in one single fraction: 15 Gy
to the PTVCTV and 20 Gy to the PTVGTV. The 20 Gy
single dose is equivalent to a 73.7 Gy dose in 2 Gy
fractions (EQD2, α/β 4.7), resulting in a 100% 5 year
tumor control probability for cT1N0 tumors [31, 32].
The single 15 Gy dose corresponds to an EQD2 of
44.1 Gy (α/β 4.7), similar to the standard hypofractio-
nated schedule of 16 fractions of 2.66 Gy at our institu-
tion. Adequate target volume coverage is defined as 99%
or more of the PTV receiving at least 95% of the
prescribed dose (Fig. 2). VMAT plans are optimized for
target volume coverage and a dose as low as possible to
the OARs, thereby not exceeding the predefined
constraints (Additional file 1) [29]. Figure 3 illustrates an
example of a single dose ablative APBI treatment plan.
Table 1 Overview inclusion and exclusion criteria ABLATIVE study
Inclusion Exclusion
World Health Organization
performance status 0–2
Legal incapacity
Females≥ 50 yearsb
with cT1N0 tumor
Known BRCA gene mutation
Females≥ 70 years
with cT1-2b (maximum 3 cm)
N0 tumor
MRI contra-indication
Tumor histology as
assessed on biopsy:
Previous history of ipsilateral breast
surgery and impaired cosmetic
outcome, as assessed by the
treating surgeon or radiation-oncologist.
- Ductal or ductolobular
invasive carcinoma
- Estrogen receptor positivity
- HER2 receptor negative
Signs of extensive ductal carcinoma
in situ on mammogram or histological
biopsy.
Unifocal tumor History of breast cancer
Tumor negative sentinel
node procedure
Other type of malignancy within
5 years before breast cancer diagnosisa, b
Adequate understanding
of the Dutch language
Collagen synthesis disease
aFor adequately treated carcinoma in situ of the cervix or basal cell carcinoma
of the skin no specific time span is required. b Criterion adjusted following
the amendment
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Radiotherapy treatment delivery
For position verification purposes 2 cone beam CTs (CBCT)
are performed before RT delivery. The first CBCT is used
for treatment position assessment, and the second one to
check the tumor location after position correction. The clip
in the tumor is used for position verification. Also the
position of the clip relative to the chest wall is determined
to quantify changes in target location or deformations. To
account for intra-fraction motion, position verification and
correction is performed after the first arc using a third
CBCT. A last CBCT is taken after RT delivery to determine
the intra-fraction motion during the second arc.
Fig. 1 Overview study design. Legend: * reassessment eligibility criteria following procedure ** additional informed consent required
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Follow-up after single dose ablative treatment
Following the ablative boost treatment, frequent clinical
and MRI monitoring will be performed. For (early) treat-
ment response assessment, MRIs are scheduled within
1 week and at 2, 4 and 6 months after RT. The radio-
logic response will be evaluated according the ‘Response
Evaluation Criteria in Solid Tumors’ guidelines [33].
Breast-conserving surgery
In order to assess the ablative RT effect on the tumor,
breast-conserving surgery is scheduled at 6 months fol-
lowing RT treatment. If disease progression is clinically
or radiologically suspected, surgery is performed earlier.
The surgical specimen is evaluated for radiotherapy re-
sponse. Cell viability is assessed using hematoxylin and
eosin staining, and additional cytokeratin 8 immunohisto-
chemistry. The pathological response is categorized as [34]:
1. Complete pathologic response = either no residual
carcinoma or no residual invasive carcinoma but
DCIS may be present.
2. Partial response to therapy:
• near complete response = minimal residual disease
(<10% tumor cells)
• evidence of response (10–50% tumor cells)
• >50% tumor cellularity remains evident with features
of response present
3. No evidence of response
The excision specimens will be revised centrally at the
UMC Utrecht by one dedicated breast pathologist.
Fig. 2 Contouring of planning target volumes and organs at risk. Legend: GTV represents the gross tumor volume, CTV the clinical target volume
and PTV the planning target volume
Fig. 3 Dosimetry treatment plan single dose ablative radiotherapy.
Legend: The red isodose (20 Gy) represents the prescribed dose to
the gross tumor volume (GTV), the orange isodose (19 Gy)
represents 95% of the prescribed dose to the GTV, the yellow
isodose (16 Gy) represents 107% of the prescribed dose to the
clinical target volume (CTV) and the green isodose (14.3 Gy)
represents 95% of the prescribed dose to the CTV
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Follow-up
In our institute, follow-up visits after treatment usually
consist of a yearly consultation at the outpatient depart-
ment of Surgery or Radiation Oncology including mam-
mography during 5 years. If systemic therapy is indicated,
additional consultations with the medical oncologist are
planned. Figure 4 illustrates the additional study proce-
dures and follow-up time points for the study patients.
Consultations with the radiation oncologist are scheduled
at baseline and at predefined time points up to 10 years
post diagnosis to assess long-term toxicity (Common
Toxicity Criteria Adverse events version 4.03) [35].
Reporting and follow-up of (serious) adverse events is car-
ried out according to predefined regulations of the study
protocol. Cosmetic outcome is assessed (as excellent,
good, fair and poor) by the radiation oncologist, thereby
taking into account breast changes such as telangiectasia
or fibrosis following treatment. For additional cosmetic
evaluation, digital photographs of the breasts are taken
and will be examined using the BCCT.core software pro-
gram [36]. Patients will also fill out questionnaires on the
cosmetic outcome of their breasts. Radiological follow-up
will consist of yearly mammograms in the first 5 years and
in the 6th, 8th and 10th year after RT. In addition, a diag-
nostic MRI of the breasts will be performed at 1 year after
diagnosis.
Patient reported outcome measures Patients are re-
quested to fill out questionnaires on quality of life
(EORTC QLQ-C30, EORTC QLQ-B23) [37], emotional
symptoms (Hospital Anxiety and Depression Scale) [38],
frailty (Groningen Frailty Indicator) [39] and functionality
(Multidimensional Fatigue Inventory; Short Questionnaire
to Assess Health enhancing Physical activity) [40, 41] at
baseline and predefined time points up to 10 years after
diagnosis. Furthermore, the patient’s satisfaction with the
cosmetic outcome is assessed with a standardized set of
questions.
Other procedures Even though RT is a key modality for
breast cancer treatment, no gene-expression profiles enab-
ling a personalized treatment approach are available for
the clinical practice [42]. In order to also contribute to the
evolving field of radiogenomics, study patients will be re-
quired to give additional consent for a future study on
radiotherapy response genotyping. For this purpose, an
additional breast biopsy will be performed at baseline, and
this tissue will be fresh frozen at the UMC Utrecht Bio-
bank. Also, following breast-conserving surgery, a part of
the irradiated excision specimen will be preserved.
Sample size calculation
We expect to find a pathological complete response in
95% of the patients, as determined in the surgical speci-
men at six months after radiotherapy (with or without
endocrine treatment). The sample size calculation is
performed with the Power Analysis and Sample Size soft-
ware program PASS 2008, (Hintze J, 2008. PASS 2008,
NCSS, LCC. Kaysville, Utah, USA. www,ncss,com), using
the exact (Clopper-Pearson) confidence interval formula
in the ‘Confidence intervals for one proportion’ procedure.
With an estimated pCR of 95% a sample size of 20
patients would produce a two-sided 95% confidence inter-
val running from 75 to 100%. A total of 25 patients will be
included to compensate for drop out or loss to follow-up.
Fig. 4 Overview study procedures and follow-up time
Charaghvandi et al. BMC Cancer  (2017) 17:181 Page 6 of 9
Statistical methods
The proportion of patients with pCR will be evaluated
and a two-sided 95% confidence interval will be calcu-
lated. The secondary study objectives will be described
without the performance of an official statistical test.
Discussion
The ABLATIVE study is, to the best of our knowledge,
the first study to evaluate the ablative effect of single
dose APBI for early-stage breast cancer in current era of
image-guided radiotherapy.
When pursuing a minimally burdening ablative treat-
ment for early-stage breast cancer, external beam APBI
offers the least invasive technique with the most wide-
spread availability, when compared to brachytherapy or
intraoperative techniques. A phase I dose escalation trial
with 15, 18 or 21 Gy single dose RT delivered to T1 tu-
mors has previously been evaluated in prone treatment
approach [24]. Breast-conserving surgery was performed
at 10 days after RT. During a median follow-up of
23 months, no dose limiting toxicity or local recurrences
were observed, along with good or excellent cosmetic
outcomes in all single dose APBI treated patients.
Pathological complete response following single dose
APBI will be assessed by breast-conserving surgery
6 months afterwards. Local tumor control following whole
breast RT only has been reported as feasible in two previ-
ous studies, performed more than two decades ago [32,
43]. In breast cancer patients with T1 carcinomas treated
with a hyperfractionated 45–110 Gy schedule, the 5-year
local control rates ranged from 40 up to 100% [32]. An-
other retrospective study evaluated hyperfractionated
whole breast RT alone (median dose 76 Gy) in 319 pa-
tients with stage I-IV disease, unfit for surgery or with
unresectable tumors [38]. For the total group of patients,
local control rates were 56 and 44%, at 5 and 10 years
follow-up, respectively. High-risk characteristics such as
tumor size above 4 cm and high tumor grade were inde-
pendent factors associated with local recurrence. The
mean time to maximal response was 6.4 months. In an-
other study in rectal adenocarcinoma, a time interval
around 15–16 weeks after neoadjuvant chemoradiother-
apy was evaluated as most adequate to result in a patho-
logical complete response [44]). For the current study, a
6 months interval up between radiotherapy and breast-
conserving surgery was considered acceptable from a pa-
tient’s perspective. Our results will show if 6 months
follow-up is sufficient to enable the evaluation of a
complete ablative effect. We consider a 95% pCR rate as
minimum rate to take the investigational treatment to a
future randomized controlled trial with breast-conserving
therapy as standard treatment arm. Irrespective of the
proportion of patients with a pathological complete re-
sponse, the current study might have other benefits for
clinical practice. A non-ablative preoperative single dose
treatment is an appealing alternative to multiple postopera-
tive RT fractions. In addition, extending the time to surgery
might be considered if the treatment is not ablative at
6 months following RT. Regardless of the feasibility of an
ablative treatment approach, studying preoperative RT has
great potential towards a personalized and tailored RT ap-
proach. Whereas RT is an essential part of current early-
stage breast cancer treatment, its effect cannot be directly
evaluated since surgery is performed before WBI. For the
individual patient in clinical practice, there are no predic-
tors or biomarkers of RT response available yet. With pre-
operative RT, its effect can be directly investigated in the
excised specimen, enabling future explorations towards RT
response predictors and biomarkers.
A challenge of the current study design is setting-up the
radiological follow-up between RT and surgery. The first
MRI scan, performed within 1 week after RT, aims at
identifying early-stage characteristics of treatment response.
Data from neoadjuvant chemotherapy (NAC) for locally
advanced breast cancer, have shown that the ADC values
following the first cycle of NAC significantly increased from
baseline, in complete and partial responders [45]. Further-
more, the previously mentioned single dose preoperative
APBI study evaluated changes in CE-parameters (e.g. area
under the contrast curve) and increase in ADC-values on
the MRI performed at 1 week after radiotherapy. However,
the clinical implications of these early MRI changes ought
to be further explored [46]. Since there is no experience on
RT response monitoring in breast cancer patients, add-
itional MRIs were pragmatically scheduled at 2, 4 and
6 months following single fraction APBI. In addition, we in-
corporated 2 FDG-PET-CTs at baseline and preoperatively
at 6 months, in order to evaluate other modalities for re-
sponse assessment. MRI combined with FDG-PET-CT
might have a complementary role for pCR assessment, as
suggested in neoadjuvant chemotherapy studies [47]. The
study results will have to identify the most useful imaging
modality and time point for response assessment.
For future implementation of non-invasive ablative APBI,
the performance of a separate sentinel node biopsy (SNB)
has to be addressed. A SNB is performed for staging pur-
poses only, and not with a therapeutic intent. For a select
group of low-risk patients, axillary ultrasound instead of SNB
might be perceived as sufficient to exclude (clinically rele-
vant) gross nodal involvement [48], given its high specificity
(range 82–98%) [49]. The impact of non-detection of micro-
metastases is limited, with similar survival in women with
stage IA (node negative) versus stage IB disease (micrometas-
tases) [50]. Currently, the omission of SNB is being prospect-
ively evaluated for cT1-2 N0 disease as assessed with axillary
ultrasound, treated with breast-conserving therapy [51].
At our department, the ABLATIVE study with a single
dose treatment is a preparatory step towards on-line MRI-
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guided RT in early-stage breast cancer. The UMC Utrecht
has, in collaboration with Elekta® and Philips®, designed and
prototyped the world’s first hybrid linear accelerator (MR-
linac) consisting of a RT delivery system and a 1.5 Tesla
MRI scanner [52]. The MR-linac provides real-time soft-
tissue imaging during the actual radiation delivery [53].
Due to this targeted approach, smaller RT target volumes
possibly reducing RT related toxicity, and RT dose escal-
ation may be facilitated at the same time. The MR-linac has
thus the potential to offer non-invasive, utterly precise,
high-dose RT as an alternative for surgical treatment.
In conclusion, the ABLATIVE study is a multicenter
prospective trial evaluating MRI-guided single dose abla-
tive radiotherapy as definitive treatment in patients with
low-risk and early-stage breast cancer.
Additional file
Additional file 1: Overview dose prescription and constraints [29].
(JPEG 115 kb)
Abbreviations
APBI: Accelerated partial breast irradiation; ASTRO: American Society for Radiation
Oncology; BSC: Breast-conserving surgery; CBCT: Cone beam CT scan; CE: Contrast
enhanced; CTV: Clinical target volume (CTV); ESTRO: European Society for
Radiotherapy and Oncology; GTV: Gross tumor volume; MR-linac: MRI linear
accelerator; NAC: Neoadjuvant chemotherapy; OAR: Organ at risk; pCR: Pathological
complete response; PTVCTV: Planning target volume of the clinical target volume;
PTVGTV: Planning target volume of the gross tumor volume; SNB: Sentinel node
biopsy; VMAT: Volumetric modulated arc therapy; WBI: Whole breast irradiation
Acknowledgements
We acknowledge C. van Kesteren for his editing work on the figures of this
manuscript.
Funding
This study is financially supported by Pink Ribbon (grant number:
2012.WO22.C154) that has no role in the collection, analysis, interpretation of
results or writing of manuscripts.
Availability of data and materials
Not applicable – data collection is still ongoing.
Authors’ contribution
HJGDB, BA, MEPP, HMV, CHG, PD, RP, MH, AW, TD, EW, TCH, MV and RKC set up
the study design and/or study protocols. RKC, PD, RP, MH, AW, TD, RK and HJGDB
are currently involved in study implementation. RKC, BA, HMV and HJGDB drafted
the manuscript. All authors reviewed and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical committee approval of the University Medical Center Utrecht (reference
number 13–659) was obtained for the ABLATIVE study. The study has been
approved by the institutional review board of University Medical Center
Utrecht, Diakonessenhuis hospital in Utrecht, St. Antonius Hospital in
Nieuwegein/Utrecht and Rivierenland Hospital in Tiel. The study is published
under NCT02316561 on ClinicalTrials.gov and has been registered on the 10th
of October 2014. Written informed consent is obtained from all participants.
Author details
1Department of Radiation Oncology, University Medical Center Utrecht,
Utrecht, The Netherlands. 2Imaging Division, University Medical Center
Utrecht, Utrecht, The Netherlands. 3Julius Center, University Medical Center
Utrecht, Utrecht, The Netherlands. 4Department of Pathology, University
Medical Center Utrecht, Utrecht, The Netherlands. 5Department of Radiology
and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The
Netherlands. 6Department of Surgery, University Medical Center Utrecht,
Utrecht, The Netherlands. 7Department of Surgery, Diakonessenhuis, Utrecht,
The Netherlands. 8Department of Medical Oncology, University Medical
Center Utrecht, Utrecht, The Netherlands. 9Department of Surgery, St.
Antonius, Nieuwegein, The Netherlands.
Received: 8 September 2016 Accepted: 15 February 2017
References
1. Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus
mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC
10801 phase 3 randomised trial. Lancet Oncol. 2012;13(4):412–9.
2. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized
trial comparing total mastectomy, lumpectomy, and lumpectomy plus
irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;
347(16):1233–41.
3. Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after
breast-conserving surgery on 10-year recurrence and 15-year breast cancer
death: meta-analysis of individual patient data for 10,801 women in 17
randomised trials. Lancet. 2011;378(9804):1707–16.
4. Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or
without irradiation in women aged 65 years or older with early breast
cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):
266–73.
5. Huang E, Buchholz TA, et al. Classifying local disease recurrences after breast
conservation therapy based on location and histology: new primary tumors
have more favorable outcomes than true local disease recurrences. Cancer.
2002;95(10):2059–67.
6. Cajucom CC, Tsangaris TN, et al. Results of salvage mastectomy for local
recurrence after breast-conserving surgery without radiation therapy.
Cancer. 1993;71(5):1774–9.
7. Polgár C, Van Limbergen E, Potter R, et al. Patient selection for accelerated
partial-breast irradiation (APBI) after breast-conserving surgery:
Recommendations of the Groupe Européen de Curiethérapie European
Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer
working group based on clinical evidence (2009). Radiat Oncol. 2010;94:264–73.
8. Smith BD, Douglas WA, Buchholz TA, et al. Accelerated partial breast
irradiation consensus statement from the American Society for Radiation
Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001.
9. Theberge V, Whelan T, Shaitelman SF, et al. Altered fractionation: rationale
and justification for whole and partial breast hypofractionated radiotherapy.
Semin Radiat Oncol. 2011;21(1):55–65.
10. Marta GN, Macedo CR, Hde Carvalho A, et al. Accelerated partial irradiation
for breast cancer: systematic review and meta-analysis of 8653 women in
eight randomized trials. Radiother Oncol. 2015;114(1):42–9.
11. Polgar C, Fodor J, Major T, et al. Breast-conserving therapy with partial or
whole breast irradiation: ten-year results of the Budapest randomized trial.
Radiother Oncol. 2013;108(2):197–202.
12. Rodriguez N, Sanz X, Dengra J, et al. Five-year outcomes, cosmesis, and
toxicity with 3-dimensional conformal external beam radiation therapy to
deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys.
2013;87(5):1051–7.
13. Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using
intensity-modulated radiotherapy versus whole breast irradiation: 5-year
survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;
51(4):451–63.
14. Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results
from RAPID: a randomized trial of accelerated partial breast irradiation using
three-dimensional conformal external beam radiation therapy. J Clin Oncol.
2013;31(32):4038–45.
15. Leonard C, Carter D, Kercher J, et al. Prospective trial of accelerated partial
breast intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;
67(5):1291–8.
Charaghvandi et al. BMC Cancer  (2017) 17:181 Page 8 of 9
16. Lewin AA, Derhagopian R, Saigal K, et al. Accelerated partial breast
irradiation is safe and effective using intensity-modulated radiation therapy
in selected early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012;82(5):
2104–10.
17. Coles C, Agrawal R, Ah-See ML, et al. Partial breast radiotherapy for women
with early breast cancer: First results of local recurrence data for IMPORT
LOW (CRUK/06/003) in the 10th European Breast Cancer Conference; 2016
March 9–11; Amsterdam. Abstract nr. 4LBA.
18. Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial
breast irradiation using sole interstitial multicatheter brachytherapy versus
whole-breast irradiation with boost after breast-conserving surgery for low-
risk invasive and in-situ carcinoma of the female breast: a randomised,
phase 3, non-inferiority trial. Lancet. 2016;387(10015):229–38.
19. Leonardi MC, Maisonneuve P, Mastropasqua MG, et al. Accelerated partial breast
irradiation with intraoperative electrons: using GEC-ESTRO recommendations as
guidance for patient selection. Radiother Oncol. 2013;106(1):21–7.
20. van der Leij F, Elkhuizen PH, Janssen TM, et al. Target volume delineation in
external beam partial breast irradiation: less inter-observer variation with
preoperative- compared to postoperative delineation. Radiother Oncol.
2014;110(3):467–70.
21. Den Hartogh MD, Philippens ME, Van Dam IE, et al. Post-lumpectomy CT-
guided tumor bed delineation for breast boost and partial breast irradiation:
Can additional pre- and postoperative imaging reduce interobserver
variability? Oncol Lett. 2015;10(5):2795–801. doi:10.3892/ol.2015.3697.
22. Palta M, Yoo S, Adamson JD, Prosnitz LR, et al. Preoperative single fraction
partial breast radiotherapy for early-stage breast cancer. Int J Radiat Oncol
Biol Phys. 2012;82(1):37–42.
23. Nichols EM, Dhople AA, Mohiuddin MM, Flannery TW, Yu CX, Regine WF.
Comparative analysis of the post-lumpectomy target volume versus the use
of pre-lumpectomy tumor volume for early-stage breast cancer:
implications for the future. Int J Radiat Oncol Biol Phys. 2010;77(1):197–202.
24. Horton JK, Blitzblau JC, Yoo S, et al. Preoperative single-fraction partial
breast radiation therapy: a novel phase 1 dose escalation protocol with
radiation response biomarkers. Int J Radiat Oncol Biol Phys. 2015;92:846–55.
25. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus
lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis
of two randomised trials. Lancet Oncol. 2015;16(6):630–7. doi:10.1016/S1470-
2045(15)70168-3.
26. Kwaliteitsborging mensgebonden onderzoek: Nederlandse Federatie van
Universitair Medische Centra. http://www.nfu.nl/img/pdf/NFU-12.6053_
Kwaliteitsborging_mensgebonden_onderzoek_2.0.pdf. Accessed 20 Jul 2016.
27. Knuttel FM, Menezes GL, van Diest PJ, et al. Meta-analysis of the concordance
of histological grade of breast cancer between core needle biopsy and
surgical excision specimen. Br J Surg. 103(3):644–55. doi:10.1002/bjs.10128.
28. Horst KC, Ikeda DM, Fero KE, et al. Breast magnetic resonance imaging alters
patient selection for accelerated partial breast irradiation. Am J Clin Oncol.
2014;37(3):248–54.
29. Charaghvandi RK, den Hartogh MD, van Ommen AM, et al. MRI-guided
single fraction ablative radiotherapy for early-stage breast cancer: a
brachytherapy versus volumetric modulated arc therapy dosimetry study.
Radiother Oncol. 2015;117(3):477–82.
30. Van Heijst TC, Philippens ME, Charaghvandi RK, et al. Quantification of intra-
fraction motion in breast radiotherapy using supine magnetic resonance
imaging. Phys Med Biol. 2016;61(3):1352–70.
31. START Trialists’ Group. The UK Standardisation of Breast Radiotherapy
(START) Trial A of radiotherapy hypofractionation for treatment of early
breast cancer: a randomised trial. Lancet Oncol. 2008;9:331–41.
32. Van Limbergen E, Van der Schueren E, Van den Bogaert W, et al. Local
control of operable breast cancer after radiotherapy alone. Eur J Cancer.
1990;26:674–9.
33. RECIST, the official site of the RECIST Working Group guidelines. 2009.
http://www.eortc.org/recist. Accessed 22 Jul 2016.
34. Pinder SE, Provenzano E, Earl H, et al. Laboratory handling and histology
reporting of breast specimens from patients who have received
neoadjuvant chemotherapy. Histopathology. 2007;50(4):409–17.
35. U.S. Department of Health and Human Services. Common Terminology
Criteria for Adverse Events (CTCAE) version 4.03. 2010. http://evs.nci.nih.gov/
ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed
22 Jul 2016.
36. Cardoso MJ, Cardoso J, Amaral N, et al. Turning subjective into objective:
the BCCT.core software for evaluation of cosmetic results in breast cancer
conservative treatment. Breast. 2007;16(5):456–61.
37. EORTC website: quality of life questionnaires. http://groups.eortc.be/qol/
Accessed 8 Feb 2017.
38. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67(6):361–70.
39. Steverink N, Slaets JPJ, Schuurmans H, et al. Measuring frailty: development
and testing of the Groningen Frailty Indicator (GFI). Gerontologist. 2001;
41(special issue 1):236–7.
40. Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory
(MFI) psychometric qualities of an instrument to assess fatigue. J
Psychosom Res. 1995;39(3):315–25.
41. Wendel-Vos GC, Schuit AJ, Saris WH, et al. Reproducibility and relative
validity of the short questionnaire to assess health-enhancing physical
activity. J Clin Epidemiol. 2003;56(12):1163–9.
42. Gue G, Yan S, Hongha Z, et al. Radiogenomics helps to achieve
personalized therapy by evaluating patient response to radiation treatment.
Carcinogenesis. 2015;36(3):307–17.
43. Thomas F, Arriagada R, Mouriesse H, et al. Radical radiotherapy alone in
non-operable breast cancer: the major impact of tumor size and histological
grade on prognosis. Radiother Oncol. 1988;13(4):267–76.
44. Sloothaak DA, Geijsen DE, van Leersum, et al. Optimal time interval
between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J
Surg. 2013;100(7):933–9.
45. Li XR, Cheng LQ, Liu M, et al. DW-MRI ADC values can predict treatment
response in patients with locally advanced breast cancer undergoing
neoadjuvant chemotherapy. Med Oncol. 2012;29(2):425–31.
46. Wang C, Horton JK, Yin FF, et al. Assessment of treatment response with
diffusion-weighted MRI and dynamic contrast-enhanced MRI in patients
with early-stage breast cancer treated with single-dose preoperative
radiotherapy: initial results. Technol Cancer Res Treat. 2016;15(5):651–60. doi:
10.1177/1533034615593191.
47. Liu Q, Wang C, Li P, et al. The role of (18)F-FDG PET/CT and MRI in assessing
pathological complete response to neoadjuvant chemotherapy in patients
with breast cancer: a systematic review and meta-analysis. Biomed Res Int.
2016;2016:3746232. doi:10.1155/2016/3746232.
48. Tucker NS, Cyr AE, Ademuyiwa FO, et al. Axillary Ultrasound Accurately
Excludes Clinically Significant Lymph Node Disease in Patients With Early
Stage Breast Cancer. Ann Surg. 2016; 254(6):1098–102.
49. Cools-Lartigue J, Meterissian S. Accuracy of axillary ultrasound in the
diagnosis of nodal metastasis in invasive breast cancer: a review. World J
Surg. 2012;36(1):46–54.
50. Mittendorf EA, Ballman KV, McCall LM, et al. Evaluation of the stage IB
designation of the American Joint Committee on Cancer staging system in
breast cancer. J Clin Oncol. 2015;33(10):1119–27.
51. Study protocol Omitting Sentinel Node Procedure in Breast Cancer Patients
Undergoing Breast Conserving Therapy. 2014. https://clinicaltrials.gov/ct2/
show/NCT02271828. Accessed 22 Jul 2016.
52. Raaymakers BW, Lagendijk JJ, Overweg J, et al. Integrating a 1.5T MRI
scanner with a 6 MV accelerator: proof of concept. Phys Med Biol. 2009;
54(12):N229–37.
53. Crijns SP, Raaymakers BW, Lagendijk JJ. Proof of concept of MRI-guided
tracked radiation delivery: tracking one-dimensional motion. Phys Med Biol.
2012;57(23):7863–72.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Charaghvandi et al. BMC Cancer  (2017) 17:181 Page 9 of 9
